GDTC
CytoMed Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$0.98
+10.61%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.87
From 52W high−63.57%
Volume20671.00
Market cap$11.60M
P/E (TTM)—
P/S (TTM)23.0x
Div yield—
Key dataSep 18, 2026
Open
$0.87
From 52W high
−63.57%
Volume
20671.00
Market cap
$11.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
40.7
MomentumView details →
1D Return
+10.61%
YTD Return
−42.51%
SummaryUpdated Dec 1, 2025
CytoMed Therapeutics Limited (NASDAQ:GDTC) is a Singapore-based pre-clinical biopharmaceutical company founded in 2018 that specializes in developing novel cell-based immunotherapies for cancer treatment. The company went public in April 2023 and focuses on harnessing the power of gamma delta T cells and other immune cells to create innovative cancer treatments. As a pre-clinical stage company, CytoMed is currently developing its pipeline of experimental therapies without any approved products on the market.
Similar companies
Latest newsMore news →
No recent news for GDTC.